Colorectal Cancer Screening in Lynch Syndrome: Indication, Techniques and Future Perspectives - PubMed

Colorectal Cancer Screening in Lynch Syndrome: Indication, Techniques and Future Perspectives - PubMed

Colorectal Cancer Screening in Lynch Syndrome: Indication, Techniques and Future Perspectives

Guillaume Perrod 1 2, Gabriel Rahmi 1 2, Christophe Cellier 1 2

Affiliations 

• PMID: 32314431
 
• DOI: 10.1111/den.13702

Abstract

Lynch syndrome (LS) is an inherited predisposition to colorectal cancer (CRC), responsible for 3-5% of all CRC. This syndrome is characterized by the early occurrence of colorectal neoplastic lesions, with variable incidences depending on the type of pathogenic variants in MMR genes (MLH1, MSH2, MSH6, PMS2 and EPCAM) and demographics factors such as gender, body mass index, tobacco use and physical activity. Similar to sporadic cancers, colorectal screening by colonoscopy is efficient because it is associated with a reduction greater than 50% of both CRC incidence and CRC related mortality. To that end, most guidelines recommend high definition screening colonoscopies in dedicated centers, starting at the age of 20-25 years old, with a surveillance interval of 1-2 years. In this review, we discuss the importance of high definition colonoscopies, including the compliance to specific key performance indicators, as well as the expected benefits of specific imaging modalities including virtual chromoendoscopy and dye-spray chromoendoscopy.

This article is protected by copyright. All rights reserved.

Similar articles

• Associations Between Mutations in MSH6 and PMS2 and Risk of Surveillance-detected Colorectal Cancer.

  Lamba M, Wakeman C, Ebel R, Hamilton S, Frampton C, Kiesanowski M, Griffiths B, Keating J, Parry S, Chalmers-Watson T.Clin Gastroenterol Hepatol. 2020 Mar 30:S1542-3565(20)30425-0. doi: 10.1016/j.cgh.2020.03.048. Online ahead of print.PMID: 32240831
• Associations of Pathogenic Variants in MLH1, MSH2, and MSH6 With Risk of Colorectal Adenomas and Tumors and With Somatic Mutations in Patients With Lynch Syndrome.

  Engel C, Ahadova A, Seppälä TT, Aretz S, Bigirwamungu-Bargeman M, Bläker H, Bucksch K, Büttner R, de Vos Tot Nederveen Cappel WT, Endris V, Holinski-Feder E, Holzapfel S, Hüneburg R, Jacobs MAJM, Koornstra JJ, Langers AM, Lepistö A, Morak M, Möslein G, Peltomäki P, Pylvänäinen K, Rahner N, Renkonen-Sinisalo L, Schulmann K, Steinke-Lange V, Stenzinger A, Strassburg CP, van de Meeberg PC, van Kouwen M, van Leerdam M, Vangala DB, Vecht J, Verhulst ML, von Knebel Doeberitz M, Weitz J, Zachariae S, Loeffler M, Mecklin JP, Kloor M, Vasen HF; German HNPCC Consortium, the Dutch Lynch Syndrome Collaborative Group; Finnish Lynch Syndrome Registry.Gastroenterology. 2020 Apr;158(5):1326-1333. doi: 10.1053/j.gastro.2019.12.032. Epub 2020 Jan 8.PMID: 31926173
• Germline MLH1, MSH2 and MSH6 variants in Brazilian patients with colorectal cancer and clinical features suggestive of Lynch Syndrome.

  Schneider NB, Pastor T, Paula AE, Achatz MI, Santos ÂRD, Vianna FSL, Rosset C, Pinheiro M, Ashton-Prolla P, Moreira MÂM, Palmero EI; Brazilian Lynch Syndrome Study Group.Cancer Med. 2018 May;7(5):2078-2088. doi: 10.1002/cam4.1316. Epub 2018 Mar 25.PMID: 29575718 Free PMC article. Clinical Trial.
• Molecular testing for Lynch syndrome in people with colorectal cancer: systematic reviews and economic evaluation.

  Snowsill T, Coelho H, Huxley N, Jones-Hughes T, Briscoe S, Frayling IM, Hyde C.Health Technol Assess. 2017 Sep;21(51):1-238. doi: 10.3310/hta21510.PMID: 28895526 Free PMC article. Review.
• Current clinical topics of Lynch syndrome.

  Tanakaya K.Int J Clin Oncol. 2019 Sep;24(9):1013-1019. doi: 10.1007/s10147-018-1282-7. Epub 2018 May 9.PMID: 29744602 Review.